Biosynex SA (FRA:0DL)
Germany · Delayed Price · Currency is EUR 0.9720
-0.1480 (-13.21%)
At close: Jan 30, 2026
Biosynex Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 97.95 | 101.17 | 92.98 | 196.59 | 382.53 | 153.9 |
| 97.95 | 101.17 | 92.98 | 196.59 | 382.53 | 153.9 | |
Revenue Growth (YoY) | -5.87% | 8.81% | -52.70% | -48.61% | 148.57% | 337.54% |
Cost of Revenue | 40.45 | 43.75 | 43.85 | 94.26 | 176.12 | 84.58 |
Gross Profit | 57.5 | 57.42 | 49.13 | 102.33 | 206.41 | 69.32 |
Selling, General & Admin | 36.2 | 41.38 | 36.06 | 21.44 | 17.25 | 14.58 |
Amortization of Goodwill & Intangibles | 16.29 | - | - | 5.72 | - | - |
Other Operating Expenses | 26.89 | 16.06 | 24.6 | 25.64 | 41.9 | 2.36 |
Operating Expenses | 100.12 | 84.95 | 85.28 | 63.44 | 65.76 | 23.58 |
Operating Income | -42.62 | -27.53 | -36.15 | 38.88 | 140.65 | 45.73 |
Interest Expense | -4.14 | -2.96 | -2.08 | -0.5 | -0.35 | -0.22 |
Earnings From Equity Investments | -0.16 | -0.1 | -1.51 | -5.57 | -2.68 | -0.85 |
Currency Exchange Gain (Loss) | -0.03 | - | - | - | - | - |
Other Non Operating Income (Expenses) | -0.97 | -3.27 | 3 | 0.75 | 0.35 | -0.13 |
EBT Excluding Unusual Items | -47.91 | -33.86 | -36.74 | 33.56 | 137.98 | 44.53 |
Impairment of Goodwill | -8.8 | -8.8 | -1.26 | - | - | - |
Gain (Loss) on Sale of Investments | -3.47 | - | -3.98 | -3.45 | - | 0.06 |
Asset Writedown | -11.45 | - | - | - | - | - |
Other Unusual Items | -2.67 | -2.09 | 2.3 | -5.93 | -1.04 | -1.07 |
Pretax Income | -74.3 | -44.75 | -39.68 | 24.18 | 136.94 | 43.52 |
Income Tax Expense | -3.36 | -1.36 | -2.56 | 8.57 | 32.94 | 12.15 |
Earnings From Continuing Operations | -70.94 | -43.4 | -37.12 | 15.61 | 104 | 31.37 |
Minority Interest in Earnings | -0.05 | 0.06 | 0.18 | 0.04 | - | - |
Net Income | -70.99 | -43.33 | -36.95 | 15.66 | 104 | 31.37 |
Net Income to Common | -70.99 | -43.33 | -36.95 | 15.66 | 104 | 31.37 |
Net Income Growth | - | - | - | -84.95% | 231.54% | 2756.89% |
Shares Outstanding (Basic) | 15 | 11 | 11 | 10 | 10 | 9 |
Shares Outstanding (Diluted) | 15 | 11 | 11 | 10 | 10 | 9 |
Shares Change (YoY) | 32.73% | 0.40% | 3.96% | -0.86% | 16.59% | -2.45% |
EPS (Basic) | -4.82 | -4.03 | -3.45 | 1.53 | 10.08 | 3.52 |
EPS (Diluted) | -4.82 | -4.03 | -3.45 | 1.52 | 10.01 | 3.52 |
EPS Growth | - | - | - | -84.81% | 184.38% | 2833.33% |
Free Cash Flow | -10.16 | -14.96 | -49.2 | -32.83 | 90.82 | 22.52 |
Free Cash Flow Per Share | -0.69 | -1.39 | -4.59 | -3.19 | 8.74 | 2.53 |
Dividend Per Share | - | - | - | - | 2.000 | 0.200 |
Dividend Growth | - | - | - | - | 900.00% | - |
Gross Margin | 58.71% | 56.76% | 52.84% | 52.05% | 53.96% | 45.04% |
Operating Margin | -43.51% | -27.21% | -38.88% | 19.78% | 36.77% | 29.72% |
Profit Margin | -72.47% | -42.83% | -39.74% | 7.96% | 27.19% | 20.38% |
Free Cash Flow Margin | -10.37% | -14.79% | -52.91% | -16.70% | 23.74% | 14.63% |
EBITDA | -17.94 | -22.16 | -23.95 | 60.25 | 142.69 | 52.98 |
EBITDA Margin | -18.31% | -21.90% | -25.75% | 30.65% | 37.30% | 34.43% |
D&A For EBITDA | 24.69 | 5.37 | 12.2 | 21.36 | 2.04 | 7.25 |
EBIT | -42.62 | -27.53 | -36.15 | 38.88 | 140.65 | 45.73 |
EBIT Margin | -43.51% | -27.21% | -38.88% | 19.78% | 36.77% | 29.72% |
Effective Tax Rate | - | - | - | 35.44% | 24.05% | 27.92% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.